

REMARKS

Claims 1-10 are pending in this application. Claims 1, 2 and 4 are amended. Claim 3 is canceled. Claims 6, 8 and 9 were withdrawn by the Examiner as being drawn to a non-elected subject matter.

Claim 1 is amended to recite "A reversibly immortalized mammalian liver cell line or a passage cell line thereof, containing an immortalizing gene interposed between a pair of site-specific recombination sequences and a suicide gene in the outside of the pair of site-specific recombination sequences, wherein the suicide gene can exhibit its function after excision of the pair of site-specific recombination sequences, wherein the liver cell line or a passage cell line thereof does not contain a promoter derived from virus." Support for the amendment of can be found throughout the present specification as originally filed.

Claim 2 is amended to recite "The reversibly immortalized mammalian liver cell line or the passage cell line thereof of Claim 1, wherein the liver cell line or the passage cell line thereof comprises human liver cells." Support for these amendments can be found throughout the present specification as originally filed.

Claim 4 is amended to remove the parenthetical portion of the claim.

The amendments to the claims are made solely for advancing prosecution. Applicants, by amending or cancelling any claims herein, make no admission as to the validity of any objection and/or rejection made by the Examiner. Applicants reserve the right to reassert the original claim scope of any claim amended herein, in a continuing application.

No new matter is introduced to this application within the meaning of 35 USC §132.

In view of the following, further and favorable consideration is respectfully requested.

I. Election/Restriction

The Examiner recognizes claims 9 and 10, introduced in the Preliminary Amendment filed September 28, 2006, were not included in the Restriction Requirement. The Examiner notes claim 9 should have been included in Group II of the Restriction Requirement and claim 10 should have been included in Group I.

Further, the Examiner acknowledges the election of Group I drawn to claims 1-5, 7 and 10. The Examiner states that the election was treated as an election without traverse because Applicant did not distinctly and specifically point out the supposed errors in the restriction requirement. Applicants respectfully submit the Examiner incorrectly characterized Applicants Response filed October 29, 2009. Applicants direct the Examiner's attention to page 3 of the Response where Applicants explain no serious burden exists to search and examine the entire application. Applicants maintain the election was made with traverse and a proper explanation of the errors of the Restriction Requirement was distinctly and specifically set forth in the Response filed October 29, 2009. Accordingly, the restriction is improper, and the claims should all be prosecuted together in the present application.

II. Rejection of Claims 32 and 33 under 35 U.S.C. §112, 2nd paragraph

Claims 2-5, 7 and 10 are rejected under 35 U.S.C. §112, 2nd paragraph as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

With regard to claim 2, the Examiner asserts that the phrase “wherein said mammalian is human” is grammatically incorrect. Claim 2 is amended to recite “wherein the liver cell line or the passage cell line thereof comprises human liver cells.” Applicants respectfully submit amended claim 2 is clear and definite and request the Examiner reconsider and withdraw this rejection.

With regard to claim 3, the Examiner asserts the claim is “indefinite because it does not clearly set forth the structure of the promoter or clearly indicate from [where] the promoter cannot come.” Applicants canceled claim 3 and incorporated the limitations of claim 3 into claim 1. Claim 1 recites “A reversibly immortalized mammalian liver cell line or a passage cell line thereof, containing an immortalizing gene interposed between a pair of site-specific recombination sequences and a suicide gene in the outside of the pair of site-specific recombination sequences, wherein the suicide gene can exhibit its function after excision of the pair of site-specific recombination sequences, **wherein the liver cell line or a passage cell line thereof does not contain a promoter derived from virus.**” Claim 1 clearly recites the liver cell line or a passage cell line thereof does not contain a promoter derived from virus.

Applicants believe that a person of ordinary skill in the art would clearly understand what a promoter derived from virus means in view of the technical common knowledge at the time the present application was filed. At page 59, lines 1 to 3 of “Animal cell cultures technique and substance production”, September 2002, CMC Publishing Co., Ltd. attached herein to this Response as Appendix A, along with an English translation of the relevant section, the process of the single-stranded RNA virus being converted to double stranded DNA by the action of reverse transcriptase encoded by viral *pol* gene is described as

follows:

In this process, viral DNA has large repeat sequence called "LTR (long terminal repeat)" at each end. An activity as promoter and information for transcriptional termination LTR exist on LTR."

In other words, the reference discloses (a) LTR is generated at the two ends of DNA in the process of preparing a viral vector, and (b) that such LTR have strong promoter activity. Therefore, it is clear that the phrase "a promoter derived from virus" includes viral LTR corresponding to a promoter. Accordingly, Applicants submit the phrase "a promoter derived from virus" is clear and definite to one of ordinary skill in the art at the time the invention was made.

Applicants respectfully submit amended claim 1, which incorporates the limitations of claim 3, is clear and definite and request the Examiner reconsider and withdraw this rejection.

With regard to claim 4, the Examiner asserted the parenthetical phrase of the claim is unclear because it cannot be determined if the parenthetical is part of the claim or not. Applicants amended claim 4 to remove the parenthetical phrase. Applicants respectfully submit amended claim 4 is clear and definite and request the Examiner reconsider and withdraw this rejection.

With regard to claim 5, the Examiner asserted claim 5 is indefinite because the Examiner could not determine how the cell of claim 5 is structurally or functionally different than the cell of claim 1. The cell of claim 1 contains the immortalizing gene. In contrast, the immortalizing gene is excised from the cell of claim 5. Applicants submit the cell of claim 5 has the same function as the cell of claim 1 except for the function relating to proliferation. The functional difference was observed in Test Examples 1 and 3 and

depicted in Figures 6a, 6B and 10. Applicants respectfully submit claim 5 and dependent claim 10 are clear and definite and request the Examiner reconsider and withdraw this rejection.

Accordingly, Applicants respectfully submit that the present claims are clear and definite and respectfully request that the Examiner reconsider and withdraw this rejection.

III. Rejection of Claims 1-5, 7 and 10 under 35 U.S.C. §102(b)

The Examiner asserts that claims 2-5, 7 and 10 are anticipated by Westerman (PNAS, Aug. 1996, Vol. 93, pg 8971-8976), Salmon (Molecular Therapy, Oct. 2000, Vol. 2, No.4, pg 404-414), Kobayashi (Science, Feb. 18,2000, Vol. 287, pg 1258-1262), Kobayashi (Human Cell., March 2000, Vol. 13, No.1, pg 7-13), Kobayashi (Saisei Iryo, Nov. 2002, Vol. 1, No.2, pg 23-28) and Kobayashi (Cell Technology, June 2000, Vol. 19, No.6, pg 864-868). The Examiner asserts all of the references teach a reversibly immortalized human liver cell line containing an immortalizing gene between a pair of site-specific recombination sequences, and a suicide gene in the outside of the pair of site-specific recombination sequences, wherein the suicide gene can exhibit its function after excision of the pair of site-specific recombination sequences.

Applicants respectfully traverse this rejection. The test for anticipation is whether each and every element as set forth is found, either expressly or inherently described, in a single prior art reference. *Verdegaal Bros. v. Union Oil Co. of California*, 2 USPQ2d 1051, 1053 (Fed. Cir. 1987); MPEP §2131. The identical invention must be shown in as complete detail as is contained in the claim. *Richardson v. Suzuki Motor Co.*, 9 USPQ2d 1913, 1920 (Fed. Cir. 1989); MPEP §2131. The elements must also be arranged as

required by the claim. *In re Bond*, 15 USPQ2d 1566 (Fed. Cir. 1990).

In the present application, independent claim 1, as amended, recites “A reversibly immortalized mammalian liver cell line or a passage cell line thereof, containing an immortalizing gene interposed between a pair of site-specific recombination sequences and a suicide gene in the outside of the pair of site-specific recombination sequences, wherein the suicide gene can exhibit its function after excision of the pair of site-specific recombination sequences, wherein the liver cell line or a passage cell line thereof does not contain a promoter derived from virus.” Specifically, the liver cell line or a passage cell line thereof ***does not contain a promoter derived from virus.***

Applicants note that the specification as originally filed is amended to remove CMV promoter as a possible non-viral promoter. The CMV promoter is derived from cytomegalovirus and as such cannot be considered a ***non-viral*** promoter. By amending the specification, Applicants are correcting this improper description of the CMV promoter.

Applicants respectfully submit the instant claims are distinguishable from the teachings of all the cited references. All of the promoters described in the cited references are ***promoters derived from virus***, such as a CMV promoter and viral LTR. As mentioned above in section II, viral LTR is included in a promoter derived from a virus.

In contrast, the presently pending claims recite the liver cell line or the passage cell line thereof ***does not contain a promoter derived from virus.*** Therefore, the cited references, which all teach a promoter derived from a virus, do not teach each and every element of the presently pending claims and do not anticipate the presently pending claims.

For at least the foregoing reasons, the cited references do not anticipate presently pending claims 1-5, 7 and 10 within the meaning of 35 USC § 102(b). Accordingly, Applicants respectfully request the Examiner to reconsider and withdraw this rejection.

CONCLUSION

In view of the foregoing, Applicants submit the application is in condition for immediate allowance. Early notice to that effect is earnestly solicited. The Examiner is invited to contact the undersigned attorney if it is believed such contact will expedite the prosecution of the application.


In the event this paper is not timely filed, Applicants petition for an appropriate extension of time. Please charge any fee deficiency or credit any overpayment to Deposit Account No. 14-0112.

Respectfully submitted,

THE NATH LAW GROUP

Date: April 9, 2010

THE NATH LAW GROUP
112 South West Street
Alexandria, VA 22314
Phone: (703)548-6284
Fax: (703) 683-8396



Joshua B. Goldberg
Registration No. 44,126
Tanya E. Harkins
Registration No. 52,993
Customer No. 20529

APPENDIX A

2.2.6 宿主・ベクター系

(1) SV40-サル細胞系

SV40 ゲノムは、5243 塩基からなる 2 本鎖閉環状 DNA で、遺伝子構造やその発現が、よく解析されている。複製起点 (ori) をはさんで、初期 (DNA 合成前) 遺伝子と後期 (DNA 合成開始後) 遺伝子の 2 領域がある。前者からは、large T 抗原と small T 抗原が、後者からは、VP1, VP2 や VP3 が合成される。ウイルスの自己複製、細胞の形質転換には、large T 抗原が必要である。

SV40 をベクターとして用いる場合、アフリカミドリザル腎細胞由来の CV-1 が、宿主としてよく用いられている。組換え遺伝子を作製する際には、(i) 後期遺伝子領域に目的遺伝子を挿入する場合と (ii) 初期遺伝子領域に挿入する場合があるが、SV40 感染細胞では、後期プロモーター活性が強いために、前者を用いることが多い。Hamer と Leder²⁸⁾ は、 β ^{ma} グロビン 遺伝子を SV40 後期領域に挿入した実験より、安定な細胞質 mRNA を得るためには、組換え遺伝子が、少なくとも 1 つの、欠損のない (intact) splice junction をもたなければならないことを示した。後期置換ベクター系にて、H-ras²⁹⁾、ラットプロインシュリン³⁰⁾ そして HBsAg³¹⁾ などの発現が成功している。

SV40 が宿主細胞で自己増殖するには、前述のように、large T 抗原の存在が必須である。したがって、large T 抗原がコードされている初期領域の置換はほとんどなされなかった。しかし、Gluzman³²⁾ が CV-1 を ori 欠損の SV40 で形質転換した COS 細胞を樹立したために、この系が多用され始めた。ただ、この系では、組換え遺伝子の増幅・転写が一過性であり、細胞はやがて死滅する。インフルエンザウイルス血球凝集素遺伝子やヒト α 型インターフェロン³³⁾ の発現が成功しているが、その生産性は、後期置換ベクター系にくらべて低い。

(2) アデノウイルス-ヒト細胞系

アデノウイルス (AdV) は、直鎖状 2 本鎖の DNA であり、約 35 kb 塩基からなる大型のものである。DNA の 5' 末端には、分子量 55,000 のタンパク質が結合しているが、このタンパク質は DNA 複製におけるプライマー機能を有し、かつ感染効率にも関与している。AdV 感染ヒト細胞における AdV 遺伝子の発現は、SV40 に似ているが、かなり複雑である。AdV は 5 つの初期転写単位 (E1A, E1B, E2, E3, E4) を有し、DNA 合成後には、16.6 mp (map position) にある後期プロモーター (major late promoter, MLP) より、十数種の後期 mRNA が転写される。AdV の MLP は非常に強力であることが知られている。この系に関する詳細は、小田の総説⁵⁾ にゆずりたい。

(3) レトロウイルスベクター

レトロウイルスは、1 本鎖 RNA ウイルスであるが、感染細胞内で、ウイルスの pol 遺伝子に

2. 細胞の物質生産能増強技術

コードされている逆転写酵素により、2本鎖DNA（プロウイルス）に変換される。この過程で、ウイルスDNAは、両端にLTR（long terminal repeat）と呼ばれる大きな反復配列をもつ。LTRには、プロモーター活性や転写終結の情報が存在する。また、細胞DNAへの組込みにもLTRが関与する。

レトロウイルスベクター系は、以下に記するいくつかの特徴を有する。

- (i) 広い宿主域をもつ、
- (ii) 感染細胞内でウイルスDNAが安定である、
- (iii) 感染効率がよく、ウイルス感染により細胞が死滅しない、
- (iv) genomicあるいはsubgenomic DNAを挿入した場合に、スプライシングが起こる、
- (v) 細胞に導入できるゲノムの大きさが8～9 kbと大きい。

この系において、*c-mos*³⁴⁾、*v-rasH*³⁵⁾やラット成長ホルモン³⁶⁾の発現が報告されている。

この系に関しては、文献37)を参照していただきたい。

(4) エピゾームベクター

SV40、AdVやレトロウイルスの系では、ベクターは宿主細胞DNAに組込まれるが、細胞DNAに組込まれることなく、プラスミドレプリコンとして増殖するものがある。

③ウシパピローマウイルス (BPV) - マウス細胞系

パピローマウイルスは、SV40やポリオマウイルスなどととも、パポバウイルス群に属し、宿主に乳頭腫（良性のイボ）を誘発するウイルスである。パピローマウイルスの中のひとつ、BPVは、ハムスターやマウスに繊維芽細胞腫をおこし、培養細胞を形質転換し、フォーカス（focus）形成をひきおこすこと、これらの細胞内ではウイルスゲノムがエピゾームとして存在すること、が判明した。こうした事実から、この系に対して、細菌におけるプラスミドと同じような、ベクターとしての機能が期待された。BPVゲノムがエピゾームとして存在する細胞株として、マウスC127、NIH3T3、ラットFR3T3がある。これらの細胞では、多くの組換え遺伝子が数十コピー/細胞のエピゾームとして存在することが示されているが、例外として、HSV-*tk* 遺伝子、マウス *dhfr* 遺伝子³⁸⁾、組織適合性抗原 HLA-H 鎖遺伝子³⁹⁾、等が知られている。Lowryら⁴⁰⁾は、BPVゲノムの69%の長さの *Bam*HI-*Hin*dIII断片が、マウス細胞を形質転換するのに十分であることを示した。この系での物質生産の例を紹介したい。

[a] HBsAg の発現⁴¹⁾

HBVのsubgenomic断片を、細菌プラスミドpML2dと共にBPV（100%）に組換え、C127細胞に導入し、フォーカス形成細胞をクローン化した。大部分のクローンがHBsAgを培養中に分泌しており、糖付加が起っていた。クローン内で、組換え遺伝子はエピゾームとして存在したが、分子内再配列（rearrangement）を受けていた。

《CMC テクニカルライブラリー》発行にあたって

弊社は、1961年創立以来、多くの技術レポートを発行してまいりました。これらの多くは、その時代の最先端情報を企業や研究機関などの法人に提供することを目的としたもので、価格も一般の理工書に比べて遙かに高価なものでした。

一方、ある時代に最先端であった技術も、実用化され、応用展開されるにあたって普及期、成熟期を迎えていきます。ところが、最先端の時代に一流の研究者によって書かれたレポートの内容は、時代を経ても当該技術を学ぶ技術書、理工書としていささかも遜色のないことを、多くの方々が指摘されています。

弊社では過去に発行した技術レポートを個人向けの廉価な普及版《CMC テクニカルライブラリー》として発行することとしました。このシリーズが、21世紀の科学技術の発展にいささかでも貢献できれば幸いです。

2000年12月

株式会社 シーエムシー出版

動物細胞培養技術と物質生産

(B665)

1986年1月24日 初版 第1刷発行

2002年9月27日 普及版 第1刷発行

監修 大石 道夫

Printed in Japan

発行者 島 健太郎

発行所 株式会社 シーエムシー出版

東京都千代田区内神田1-4-2 (コジマビル)

電話 03 (3293) 2061

(印刷 株式会社ブリコ)

©M. Oishi, 2002

定価は表紙に表示してあります。

落丁・乱丁本はお取替えいたします。

ISBN4-88231-772-9 C3045

☆本書の無断転載・複写複製（コピー）による配布は、著者および出版社の権利の侵害になりますので、小社あて事前に承諾を求めて下さい。

English translation-in-part of
“Animal cell culture technique and substance production”

Page 58, line 2 from the bottom to page 59, line 3

(3) Retrovirus vector

Retrovirus is single-stranded RNA virus, but in infected cell it is converted to double-stranded DNA (provirus) by the action of reverse transcriptase encoded by viral *pol* gene. In this process, viral DNA has large repeat sequence called “LTR (long terminal repeat)” at each end. An activity as promoter and information for transcriptional termination LTR exist on LTR.”

[Copyright page]

“Animal cell culture technique and substance production”

Trade Edition printed and issued on September 27, 2002.

Editor: Oishi Michio

Publisher: Shima Kentaro

Publishing Office: CMC Publishing CO., LTD.